Your basic assumption is that the company needs to raise

New Post Public Reply Private Reply Replies (0) Message Board
Haschwald_Zimmer Drano #29868
563
Quote:
Your basic assumption is that the company needs to raise $15 million, that figure also making an unfounded assumption that they want to keep 2 million in the bank (that assumption based on what? The company has never stated any such thing.) It doesn't take 2 million bucks to "keep the lights on" and pay the rent.


The 10K stated an anticipated need of $19M. Of that $19M, $15M would be used for clinical trials. Therefore, they anticipate $4M is required for the rest of operations for the year. Therefore $2M would cover 2H 2017 which I consider to be the deal signing period. Strip the $2M if you don't think it's needed and it drops the average daily Aspire sales to 45K in my calculations. Doesn't change much.

Quote:
Despite your assumption, we do not know what their fundraising plans are. Are they negotiating with a partner? Are they, perhaps, talking to a business development company (like, for instance, Hercules or Horizon)? Are they negotiating a settlement with the Rosen firm which would bring cash into the coffers (or, alternatively, will the judge award them some damages)? Are they negotiating a loan (Leo Ehrlich has done this in the past)? Are they negotiating a private placement?

The answer to these questions is: we do not know.


Fair enough. Any of those are possibilities. I was using the simplest answer using only what was presented in the 10K and what the company has done the past three years. There was no mention of any of those options for fund raising in the 10K so I consider them less likely.

Quote:
Therefore, assuming that they are going to be selling shares to Aspire is not an assumption that we can make.

And even if they were indeed to sell shares to Aspire, how do you know that Aspire is selling and not holding such stock?

The answer to that question is: we do not know.


The company anticipated needing $10M+ more than they had on hand so fund raising is a probable event. As stated above, Aspire/Shelf are the vehicles for that mentioned in the 10K. What does Aspire do with the shares? They don't report a 5% stake so they have to sell some of them.

Quote:
Writing a post about "headwinds" in the stock, based on the sheerest speculation but assuming that it is true, is specious.


It is speculation, as is everything we discuss on a message board (you'll note my signature). It is, however, speculation based upon company provided information. It is not speculation based on possible future events such as settlements, loans and development corporations that you conjure up to avoid the possibility of the established fund raising methods.

Would you actually feel better if we found that they weren't selling shares to Aspire? At least if they are we are securing funds and have a good reason for lack of stock performance. Would you rather the stock be performing poorly in the absence of any sales? The 10K next year will give us the answer and I suspect the Aspire sales pattern will match the past three years barring a deal in 1H 2017.

Or it could be naked shorts which was what my original post was asking about before it got derailed.

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
All content of my posts is my opinion and speculation. Do not treat anything I say as fact or actionable investment advice. I participate to challenge my investment thesis from any angle possible. Please do your own due diligence.

Current Positions:
Long CTIX.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 385

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 398

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 270

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading

Top 5 Most Recently Viewed Articles

Madison Achieves Top Rank for Employment Opportunities

Updated Category News Views 256

Madison Tops Functional Employment Rankings Recently, Madison has been recognized as the leading metro area in the country for functional employment, a title derived from a comprehensive analysis by the Ludwig Institute for Shared Economic Prosperity (LISEP). This achievement highlights Madison’s robust job growth, higher wage levels, and an overall favorable work...

Continue Reading
Investors Alert: Class Actions Against WEBTOON, Elanco, and Domino's

Updated Category News Views 131

Class Action Lawsuits Overview In recent developments, Bragar Eagel & Squire, P.C., a well-known shareholder rights law firm, has informed investors about multiple class action lawsuits filed against notable companies such as WEBTOON Entertainment, Inc. (NASDAQ: WBTN), Elanco Animal Health Incorporated (NYSE: ELAN), and Domino's Pizza, Inc. (NYSE: DPZ). Shareholders in...

Continue Reading
Navigating the New Multipolar Reality: Insights for Investors

Updated Category News Views 257

The Shift to a Multipolar World: What Investors Need to Know The global landscape has transformed, moving away from a system dominated by one major power to a multipolar world. This significant shift means that traditional geopolitical assumptions guiding investors are no longer reliable. Marko Papic, Chief Strategist at BCA Research, recently underscored this point in a...

Continue Reading
Jim Cramer Discusses Broadcom's Impact on Market Corrections

Updated Category News Views 211

Market Dynamics and Broadcom's Recent Performance As the Nasdaq 100 index faces a notable correction, Broadcom Inc. (NASDAQ: AVGO) has managed to stand out with a remarkable surge of 12.82% during after-hours trading. However, renowned market analyst Jim Cramer expresses skepticism regarding its ability to reverse the overall market decline. Understanding the Market...

Continue Reading
NSFOCUS Achieves 'Stars Companies' Recognition in DDoS Sector

Updated Category News Views 137

NSFOCUS Achieves Notable Recognition in Cybersecurity In a significant development, NSFOCUS has earned recognition as a 'Stars Company' in the DDoS Protection and Mitigation Security sector by the esteemed MarketsandMarkets' 360Quadrants platform. This accolade reflects NSFOCUS's unwavering commitment to innovation and excellence in delivering cutting-edge solutions for...

Continue Reading